TNFSF13B and systemic lupus erythematosus: Indeed, two recent (the first two since the 1950s) FDA-approved therapies for SLE, belimumab (anti-BAFF) and anifrolumab (anti-IFNAR1), both took approaches similar to the approach that we lay out.